Literature DB >> 28007393

Fournier's gangrene during ACTH therapy.

Shingo Numoto1, Hirokazu Kurahashi2, Yoshiteru Azuma3, Atsushi Numaguchi4, Kozaburo Nakahara5, Takahisa Tainaka6, Michihiko Takasu2, Kiyoshi Yamakawa2, Nozomi Nago2, Taichiro Muto2, Yoshiro Kitagawa2, Akihisa Okumura2.   

Abstract

Fournier's gangrene is an infectious necrotizing fasciitis of the perineal, genital, or perianal regions and is uncommon in children. Adrenocorticotropic hormone (ACTH) is effective for the treatment of infantile spasms; however, suppression of immune function is one of the major adverse effects of this approach. We encountered a 2-month-old boy with infantile spasms that had been treated with ACTH and had developed complicating Fournier's gangrene. Strangulation of a right inguinal hernia was observed after ACTH treatment. Although surgical repair was successful and no intestinal injuries were detected, swelling and discoloration of the right scrotum developed in association with pyrexia and a severe inflammatory response. A scrotal incision revealed pus with a putrid smell. The patient was subsequently diagnosed with Fournier's gangrene complicated by septic shock and disseminated intravascular coagulation. Extensive debridement and intensive care was performed. Enterobactor aerogenes, methicillin-resistant Staphylococcus aureus, and Enterococcus faecalis were isolated from the pus. Meropenem, teicoplanin, and clindamycin were administered to control the bacterial infection. The patient was discharged from the intensive care unit without any obvious neurological sequelae. Suppression of immune function associated with ACTH therapy may have been related to the development of Fournier's gangrene in this case.
Copyright © 2016 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ACTH therapy; Fournier’s gangrene; Infant; Strangulation of inguinal hernia

Mesh:

Substances:

Year:  2016        PMID: 28007393     DOI: 10.1016/j.braindev.2016.11.012

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961



北京卡尤迪生物科技股份有限公司 © 2022-2023.